blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3186270

EP3186270 - CYCLIC UREA COMPOUNDS AS GRANZYME B INHIBITORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  25.12.2020
Database last updated on 31.05.2024
FormerThe patent has been granted
Status updated on  17.01.2020
FormerGrant of patent is intended
Status updated on  27.02.2019
FormerRequest for examination was made
Status updated on  02.06.2017
FormerThe international publication has been made
Status updated on  22.02.2017
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): AL, MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Vida Therapeutics, Inc.
887 Great Northern Way
Suite 125
Vancouver, British Columbia V5T 4T5 / CA
[2017/27]
Inventor(s)01 / CAMERON, Dale R.
2640 Number 4 Road
Richmond, British Columbia V6X 2L5 / CA
 [2017/27]
Representative(s)Hobson, David James, et al
Mathys & Squire The Shard
32 London Bridge Street
London SE1 9SG / GB
[N/P]
Former [2017/27]Hobson, David James, et al
Mathys & Squire LLP The Shard
32 London Bridge Street
London SE1 9SG / GB
Application number, filing date15827476.131.07.2015
[2017/27]
WO2015CA50725
Priority number, dateUS201462032479P01.08.2014         Original published format: US 201462032479 P
[2017/27]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016015160
Date:04.02.2016
Language:EN
[2016/05]
Type: A1 Application with search report 
No.:EP3186270
Date:05.07.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 04.02.2016 takes the place of the publication of the European patent application.
[2017/27]
Type: B1 Patent specification 
No.:EP3186270
Date:19.02.2020
Language:EN
[2020/08]
Search report(s)International search report - published on:CA04.02.2016
(Supplementary) European search report - dispatched on:EP26.02.2018
ClassificationIPC:C07K5/062, A61K38/05, A61P9/00, A61P9/10, C07K5/083, // A61K38/00
[2019/11]
CPC:
A61L2/10 (EP,US); A61M39/18 (EP,US); A61P17/00 (EP);
A61P17/02 (EP); A61P17/14 (EP); A61P43/00 (EP);
A61P9/00 (EP); A61P9/10 (EP); A61P9/14 (EP);
C07K5/06026 (EP,US); C07K5/0808 (EP,US); A61K38/00 (EP,US);
A61L2202/14 (EP,US); A61L2202/24 (EP,US); A61M2039/167 (EP,US) (-)
Former IPC [2017/27]C07K5/062, A61K38/05, A61P9/00, A61P9/10
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/27]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:CYCLISCHE HARNSTOFFVERBINDUNGEN ALS GRANZYM-B-HEMMER[2017/27]
English:CYCLIC UREA COMPOUNDS AS GRANZYME B INHIBITORS[2017/27]
French:COMPOSÉS D'URÉE CYCLIQUE EN TANT QU'INHIBITEURS DU GRANZYME B[2017/27]
Entry into regional phase22.02.2017National basic fee paid 
22.02.2017Search fee paid 
22.02.2017Designation fee(s) paid 
22.02.2017Examination fee paid 
Examination procedure22.02.2017Examination requested  [2017/27]
22.02.2017Date on which the examining division has become responsible
10.09.2018Amendment by applicant (claims and/or description)
28.02.2019Communication of intention to grant the patent
08.07.2019Fee for grant paid
08.07.2019Fee for publishing/printing paid
08.07.2019Receipt of the translation of the claim(s)
Opposition(s)20.11.2020No opposition filed within time limit [2021/04]
Fees paidRenewal fee
12.07.2017Renewal fee patent year 03
31.01.2019Renewal fee patent year 04
09.01.2020Renewal fee patent year 05
Penalty fee
Additional fee for renewal fee
31.07.201804   M06   Fee paid on   31.01.2019
31.07.201905   M06   Fee paid on   09.01.2020
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU31.07.2015
AL19.02.2020
AT19.02.2020
CY19.02.2020
CZ19.02.2020
DK19.02.2020
EE19.02.2020
ES19.02.2020
FI19.02.2020
HR19.02.2020
IT19.02.2020
LT19.02.2020
LV19.02.2020
MC19.02.2020
MK19.02.2020
MT19.02.2020
NL19.02.2020
PL19.02.2020
RO19.02.2020
RS19.02.2020
SE19.02.2020
SI19.02.2020
SK19.02.2020
SM19.02.2020
TR19.02.2020
BG19.05.2020
NO19.05.2020
GR20.05.2020
IS19.06.2020
PT12.07.2020
BE31.07.2020
IE31.07.2020
LU31.07.2020
[2022/31]
Former [2022/27]HU31.07.2015
AT19.02.2020
CY19.02.2020
CZ19.02.2020
DK19.02.2020
EE19.02.2020
ES19.02.2020
FI19.02.2020
HR19.02.2020
IT19.02.2020
LT19.02.2020
LV19.02.2020
MC19.02.2020
MT19.02.2020
NL19.02.2020
PL19.02.2020
RO19.02.2020
RS19.02.2020
SE19.02.2020
SI19.02.2020
SK19.02.2020
SM19.02.2020
TR19.02.2020
BG19.05.2020
NO19.05.2020
GR20.05.2020
IS19.06.2020
PT12.07.2020
BE31.07.2020
IE31.07.2020
LU31.07.2020
Former [2021/37]AT19.02.2020
CZ19.02.2020
DK19.02.2020
EE19.02.2020
ES19.02.2020
FI19.02.2020
HR19.02.2020
IT19.02.2020
LT19.02.2020
LV19.02.2020
MC19.02.2020
NL19.02.2020
PL19.02.2020
RO19.02.2020
RS19.02.2020
SE19.02.2020
SI19.02.2020
SK19.02.2020
SM19.02.2020
BG19.05.2020
NO19.05.2020
GR20.05.2020
IS19.06.2020
PT12.07.2020
BE31.07.2020
IE31.07.2020
LU31.07.2020
Former [2021/24]AT19.02.2020
CZ19.02.2020
DK19.02.2020
EE19.02.2020
ES19.02.2020
FI19.02.2020
HR19.02.2020
IT19.02.2020
LT19.02.2020
LV19.02.2020
MC19.02.2020
NL19.02.2020
PL19.02.2020
RO19.02.2020
RS19.02.2020
SE19.02.2020
SI19.02.2020
SK19.02.2020
SM19.02.2020
BG19.05.2020
NO19.05.2020
GR20.05.2020
IS19.06.2020
PT12.07.2020
BE31.07.2020
LU31.07.2020
Former [2021/20]AT19.02.2020
CZ19.02.2020
DK19.02.2020
EE19.02.2020
ES19.02.2020
FI19.02.2020
HR19.02.2020
IT19.02.2020
LT19.02.2020
LV19.02.2020
MC19.02.2020
NL19.02.2020
PL19.02.2020
RO19.02.2020
RS19.02.2020
SE19.02.2020
SI19.02.2020
SK19.02.2020
SM19.02.2020
BG19.05.2020
NO19.05.2020
GR20.05.2020
IS19.06.2020
PT12.07.2020
LU31.07.2020
Former [2021/13]AT19.02.2020
CZ19.02.2020
DK19.02.2020
EE19.02.2020
ES19.02.2020
FI19.02.2020
HR19.02.2020
IT19.02.2020
LT19.02.2020
LV19.02.2020
MC19.02.2020
NL19.02.2020
PL19.02.2020
RO19.02.2020
RS19.02.2020
SE19.02.2020
SI19.02.2020
SK19.02.2020
SM19.02.2020
BG19.05.2020
NO19.05.2020
GR20.05.2020
IS19.06.2020
PT12.07.2020
Former [2021/10]AT19.02.2020
CZ19.02.2020
DK19.02.2020
EE19.02.2020
ES19.02.2020
FI19.02.2020
HR19.02.2020
IT19.02.2020
LT19.02.2020
LV19.02.2020
NL19.02.2020
PL19.02.2020
RO19.02.2020
RS19.02.2020
SE19.02.2020
SI19.02.2020
SK19.02.2020
SM19.02.2020
BG19.05.2020
NO19.05.2020
GR20.05.2020
IS19.06.2020
PT12.07.2020
Former [2020/50]CZ19.02.2020
DK19.02.2020
EE19.02.2020
ES19.02.2020
FI19.02.2020
HR19.02.2020
LT19.02.2020
LV19.02.2020
NL19.02.2020
RO19.02.2020
RS19.02.2020
SE19.02.2020
SK19.02.2020
SM19.02.2020
BG19.05.2020
NO19.05.2020
GR20.05.2020
IS19.06.2020
PT12.07.2020
Former [2020/49]CZ19.02.2020
DK19.02.2020
ES19.02.2020
FI19.02.2020
HR19.02.2020
LT19.02.2020
LV19.02.2020
NL19.02.2020
RO19.02.2020
RS19.02.2020
SE19.02.2020
SK19.02.2020
SM19.02.2020
BG19.05.2020
NO19.05.2020
GR20.05.2020
IS19.06.2020
PT12.07.2020
Former [2020/48]DK19.02.2020
ES19.02.2020
FI19.02.2020
HR19.02.2020
LT19.02.2020
LV19.02.2020
NL19.02.2020
RO19.02.2020
RS19.02.2020
SE19.02.2020
SM19.02.2020
BG19.05.2020
NO19.05.2020
GR20.05.2020
IS19.06.2020
PT12.07.2020
Former [2020/47]DK19.02.2020
ES19.02.2020
FI19.02.2020
HR19.02.2020
LT19.02.2020
LV19.02.2020
NL19.02.2020
RS19.02.2020
SE19.02.2020
BG19.05.2020
NO19.05.2020
GR20.05.2020
IS19.06.2020
Former [2020/45]FI19.02.2020
HR19.02.2020
LV19.02.2020
NL19.02.2020
RS19.02.2020
SE19.02.2020
BG19.05.2020
NO19.05.2020
GR20.05.2020
IS19.06.2020
Former [2020/40]FI19.02.2020
HR19.02.2020
LV19.02.2020
RS19.02.2020
SE19.02.2020
BG19.05.2020
NO19.05.2020
GR20.05.2020
IS19.06.2020
Former [2020/39]FI19.02.2020
HR19.02.2020
LV19.02.2020
RS19.02.2020
SE19.02.2020
BG19.05.2020
NO19.05.2020
GR20.05.2020
Former [2020/38]FI19.02.2020
HR19.02.2020
LV19.02.2020
RS19.02.2020
SE19.02.2020
NO19.05.2020
GR20.05.2020
Former [2020/37]FI19.02.2020
HR19.02.2020
LV19.02.2020
RS19.02.2020
SE19.02.2020
NO19.05.2020
Former [2020/35]FI19.02.2020
NO19.05.2020
Documents cited:Search[A]WO03065987  (MERCK & CO INC [US], et al) [A] 1-15 * page 3; compound formula I * * page 8, line 9 - line 17; table I *;
 [A]WO2012076985  (UNIV BRITISH COLUMBIA [CA], et al) [A] 1-15 * page 52 - page 63; claim - *;
 [AP]WO2014153666  (VIDA THERAPEUTICS INC [CA]) [AP] 1-15* the whole document *;
 [E]WO2017132771  (VIDA THERAPEUTICS INC [CA]) [E] 1-15 * the whole document *;
 [A]  - WILLOUGHBY C A ET AL, "Discovery of potent, selective human granzyme B inhibitors that inhibit CTL mediated apoptosis", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, (20020819), vol. 12, no. 16, doi:10.1016/S0960-894X(02)00363-3, ISSN 0960-894X, pages 2197 - 2200, XP002973755 [A] 1-15 * tables 1-4 *

DOI:   http://dx.doi.org/10.1016/S0960-894X(02)00363-3
International search[A]US2003148511  (ASHTON-RICKARDT PHILIP G [US], et al) [A] 1-22 * See whole document *;
 [A]WO03065987  (MERCK & CO INC [US], et al) [A] 1-22 * See whole document *;
 [A]WO2012076985  (UNIV BRITISH COLUMBIA [CA], et al) [A] 1-22 * See whole document *;
 [PA]WO2014153666  (VIDA THERAPEUTICS INC [CA]) [PA] 1-22* See whole document *;
 [A]  - WILLOUGHBY, CA . et al., "Discovery of potent, selective human granzyme B inhibitors that inhibit CTL mediated apoptosis.", Bioorganic & Medicinal Chemistry Letters, (20020000), vol. 12, doi:doi:10.1016/S0960-894X(02)00363-3, ISSN 0960-894X, pages 2197 - 2200, XP002973755 [A] 1-22 * See whole document *

DOI:   http://dx.doi.org/10.1016/S0960-894X(02)00363-3
 [A]  - BUZZA, MS. et al., "Extracellular matrix remodeling by human granzyme B via cleavage of vitronectin, fibronectin, and laminin.", The Journal of Biological Chemistry, (20050624), vol. 280, no. 25, doi:doi:10.1074/jbc.M412001200, ISSN 0021-9258, pages 23549 - 23558, XP008128333 [A] 1-22 * See whole document *

DOI:   http://dx.doi.org/10.1074/jbc.M412001200
 [A]  - KAM, C-M. et al., "Granzymes (lymphocyte serine proteases) : characterization with natural and synthetic substrates and inhibitors.", Biochimica et Biophysica Acta, (20000000), vol. 1477, no. 1-2, doi:doi:10.1016/S0167-4838(99)00282-4, ISSN 0006-3002, pages 307 - 323, XP004278902 [A] 1-22 * See whole document *

DOI:   http://dx.doi.org/10.1016/S0167-4838(99)00282-4
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.